| Study population (n = 74) | Surgery (n = 27) | No surgery (n = 47) | P-value |
---|---|---|---|---|
Age, years, mean (SD)a | 50.6 (16.6) | 49.2 (19.6) | 51.5 (14.8) | 0.60 |
Sex-ratio (H/F) | 1.96 | 1.1 | 2.92 | 0.08 |
Underlying disease | ||||
 Hematological malignancies, n (%) | 41 (55.4) | 12 (44.4) | 29 (61.7) | 0.23 |
 Acute myeloid leukemia, n (%) | 15 (20.3) | 5 (18.5) | 10 (21.3) | 1 |
 Acute lymphoblastic leukemia, n (%) | 10 (13.5) | 3 (11.1) | 7 (14.9) | 0.74 |
 Lymphoma, n (%) | 8 (10.8) | 3 (11.1) | 5 (10.6) | 1 |
 Multiple myeloma, n (%) | 2 (2.7) | 0 | 2 (4.3) | 0.53 |
 Myelodysplastic syndrome, n (%) | 2 (2.7) | 0 | 2 (4.3) | 0.53 |
 Other, n (%) | 4 (5.4) | 1 (3.7) | 3 (6.4) | 1 |
 Allogenic HSCT, n (%) | 16 (21.6) | 3 (11.1) | 13 (27.7) | 0.14 |
 Autologous HSCT, n (%) | 7 (9.5) | 1 (3.7) | 6 (12.8) | 0.41 |
 Solid malignancies, n (%) | 4 (5.4) | 1 (3.7) | 3 (6.4) | 1 |
 SOT, n (%) | 9 (12.2) | 4 (14.8) | 5 (10.6) | 0.72 |
 Inflammatory disease, n (%) | 2 (2.7) | 1 (3.7) | 1 (2.1) | 1 |
 Systemic steroids, n (%) | 30 (40.5) | 8 (29.6) | 22 (46.8) | 0.15 |
 Diabetes, n (%) | 11 (14.9) | 1 (3.7) | 10 (21.3) | 0.05 |
Other condition, n (%) | Â | Â | Â | Â |
 Chronic alcoholism, n (%) | 8 (10.8) | 3 (11.1) | 5 (10.6) | 1 |
 Malnutrition, n (%) | 24 (32.4) | 10 (37.0) | 14 (29.8) | 0.70 |
 Drug addiction, n (%) | 1 (1.4) | 0 | 1 (2.1) | 1 |
 Chronic renal failure, n (%) | 7 (9.5) | 3 (11.1) | 4 (8.5) | 1 |
 Respiratory disease, n (%) | 15 (20.3) | 2 (7.4) | 13 (27.7) | 0.13 |
 Cirrhosis, n (%) | 1 (1.4) | 0 | 1 (2.1) | 1 |
 Trauma, n (%) | 7 (9.5) | 2 (7.4) | 5 (10.6) | 1 |
 Burn, n (%) | 3 (4.1) | 2 (7.4) | 1 (2.1) | 0.55 |
Previous antifungal therapy, n (%) | 30 (40.5) | 7 (25.9) | 23 (48.9) | 0.09 |
Site of infection | ||||
 Lungs, n (%) | 29 (39.2) | 5 (18.5) | 24 (51.1) | 0.01 |
 Skin, n (%) | 15 (20.3) | 8 (29.6) | 7 (14.9) | 0.22 |
 Sinus and ENT infection, n (%) | 1 (1.35) | 1 (1.4) | 0 | 0.36 |
 Abdomen, n (%) | 1 (1.35) | 1 (1.4) | 0 | 0.36 |
 Bones, n (%) | 1 (1.35) | 0 | 1 (2.1) | 1 |
 Infection of contiguous sites, n (%) | 13 (17.6) | 7 (25.9) | 6 (12.8) | 0.26 |
 Disseminated infection, n (%) | 14 (18.9) | 4 (14.8) | 10 (21.3) | 0.55 |
Isolated fungi | 0.02 | |||
 Rhizopus genus, n (%) | 22 (29.7) | 7 (25.9) | 15 (31.9) |  |
 Mucor genus, n (%) | 10 (13.5) | 2 (7.4) | 8 (17.0) |  |
 Rhizomucor genus, n (%) | 14 (18.9) | 4 (14.8) | 10 (21.3) |  |
 Lichtheimia genus, n (%) | 19 (25.7) | 7 (25.9) | 12 (25.5) |  |
 Cunninghamella genus, n (%) | 1 (1.4) | 0 | 1 (2.1) |  |
 Unclassified mucorales, n (%) | 9 (12.2) | 8 (29.6) | 1 (2.1) |  |
Year of admission | Â | Â | Â | 0.53 |
Severity of infection | ||||
 SAPS2, mean (SD)a | 52 (22) | 44.6 (17.5) | 56.6 (22.5) | 0.01 |
 SOFA, mean (SD)a | 9 (4) | 7.0 (3.3) | 9.9 (3.7) | 0.001 |
 Respiratory | 2.0 (1.2) | 1.5 (1.3) | 2.2 (1.1) | 0.01 |
 Cardiovascular | 1.7 (1.8) | 1.4 (1.6) | 1.9 (1.8) | 0.18 |
 Renal | 1.1 (1.2) | 1.2 (1.2) | 1.1 (1.2) | 0.63 |
 Hematological | 2.0 (1.4) | 1.4 (1.2) | 2.3 (1.5) | 0.006 |
 Neurological | 1.2 (1.5) | 0.8 (1.3) | 1.4 (1.6) | 0.08 |
 Liver | 0.8 (0.9) | 0.6 (0.8) | 0.9 (0.9) | 0.17 |
Biological abnormalities | ||||
 TP < 50%, n (%) | 13 (17.6) | 2 (7.41) | 11 (23.4) | 0.12 |
 Thrombocytes < 50G/L, n (%) | 27 (36.5) | 5 (18.5) | 22 (46.8) | 0.02 |
 Leucocytes < 1G/L, n (%) | 23 (31.1) | 6 (22.2) | 17 (36.2) | 0.32 |
 Interventions |  |  |  |  |
 Vasopressors | 53 (71.6) | 18 (66.7) | 35 (74.5) | 0.65 |
 Mechanical ventilation | 66 (89.2) | 21 (77.8) | 45 (95.7) | 0.05 |
 Renal replacement therapy | 31 (41.9) | 14 (51.9) | 17 (36.2) | 0.23 |
 Delay of efficient antifungal treatment, mean (SD)a | 9.5 (9.9) | 10.2 (8.7) | 8.9 (11.2) | 0.64 |